Novartis, Pear to develop digital therapies for schizophrenia, MS
Novartis and Pear Therapeutics have signed a deal to develop digital therapeutics for patients with schizophrenia and multiple sclerosis.
Read More
Tag: Pear
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
- Alzecure shares new preclinical data on NeuroRestore ACD856 at AD/PD conference
- Samsung Bioepis signs partnership with Sandoz for next‑generation biosimilars
